RG
VRTX icon

Rathbones Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Rathbones Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$519K Buy
1,044
+89
+9% +$39.4K ﹤0.01% 472
2026
Q1 		$426K Sell
955
-289
-23% -$135K ﹤0.01% 470
2025
Q4 		$564K Hold
1,244
– – ﹤0.01% 437
2025
Q3 		$487K Sell
1,244
-7
-0.6% -$2.92K ﹤0.01% 445
2025
Q2 		$557K Hold
1,251
– – ﹤0.01% 419
2025
Q1 		$607K Sell
1,251
-203
-14% -$94.6K ﹤0.01% 391
2024
Q4 		$586K Hold
1,454
– – ﹤0.01% 397
2024
Q3 		$676K Buy
1,454
+355
+32% +$171K ﹤0.01% 373
2024
Q2 		$515K Sell
1,099
-570
-34% -$247K ﹤0.01% 411
2024
Q1 		$698K Buy
1,669
+179
+12% +$75.7K ﹤0.01% 368
2023
Q4 		$606K Buy
1,490
+227
+18% +$83.9K ﹤0.01% 370
2023
Q3 		$439K Buy
+1,263
New +$442K ﹤0.01% 417

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Rathbones Group's VRTX Position: Q2 2026 in Review

Rathbones Group increased its Vertex Pharmaceuticals (VRTX) stake by 9.3% in Q2 2026, buying an estimated $39.4K and bringing the position to 1,044 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #472.

Rathbones Group first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $698K in Q1 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Rathbones Group held 1,044 shares of Vertex Pharmaceuticals worth $519K as of Q2 2026.
  • Rathbones Group bought 89 Vertex Pharmaceuticals shares in Q2 2026, an estimated $39.4K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #472 holding.
  • Rathbones Group first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Rathbones Group's Vertex Pharmaceuticals position peaked at $698K in Q1 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.